Bluebird bio Inc

Bluebird bio — Corporate Update (December 2023)

17 slides from Bluebird bio's corporate update, Dec 11, 2023

  1. Slide 1: LYFGENIA FDA approval

    LYFGENIA™ FDA approval December 8, 2023 NASDAQ: BLUE Exhibit 99.1

  2. Slide 2: Forward-looking statements

    These slides and the accompanying oral presentation contain certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including

  3. Slide 3: Welcome and opening remarks

    Welcome and opening remarks Andrew Obenshain, chief executive officer Clinical data and label highlights Rich Colvin, MD, PhD, chief medical officer Commercial launch plans Tom Klima, chief commercial and operating officer Closing Andrew Obenshain, chief executive officer Q&A

  4. Slide 4: LYFGENIA: Now FDA Approved

    LYFGENIA: Now FDA Approved lyFgenia” ((ovotibeglogene autotemcel) suspension for IV infusion

  5. Slide 5: LYFGENIA Clinical Data & Label Highlights

    LYFGENIA Clinical Data & Label Highlights Rich Colvin, MD, PhD, Chief Medical Officer

  6. Slide 6: Burden of sickle cell disease

    of adults with SCD have end organ damage, with 24% experiencing damage in multiple organs1 1 in 4 in direct medical costs, despite a median age of death of only 45 years old3 of individuals with SCD report giving up a job due to the disease4 1. Chaturvedi S, et al. Am J Hematol. 2018 3; 2. Kato GJ,

  7. Slide 7: LYFGENIA is a custom-designed gene therapy that is uniquely traceable

    LYFGENIA is a custom-designed gene therapy that is uniquely traceable A single mutation in the beta-globin gene leads to the production of sickled hemoglobin (HbS) rather than adult hemoglobin (HbA) LYFGENIA is manufactured by transducing autologous CD34+ cells with BB305 LVV βA-T87Q –globin pairs w

  8. Slide 8: LYFGENIA supported by the most robust and longest follow-up of any gene therapy program for SCD

    LYFGENIA supported by the most robust and longest follow-up of any gene therapy program for SCD Data as of Feb 13, 2023 *54 patients initiated cell collection in HGB-206 Group A, Group B and Group C. a sVOE is defined as a VOE requiring a hospitalization or multiple visits to an emergency department

  9. Slide 9: Commercial Launch Plans

    Commercial Launch Plans Tom Klima, Chief Commercial and Operating Officer

  10. Slide 10: Synergistic network of ZYNTEGLO QTCs preparing to treat SCD patients

    Synergistic network of 35 ZYNTEGLO QTCs preparing to treat SCD patients anticipated in early 2024 27 QTCs are ready to receive SCD patient referrals now Activated ZYNTEGLO QTC* Shading indicates target SCD market Anticipate additional QTC network expansion in 2024 100% of ZYNTEGLO QTCs have initiate

  11. Slide 11: Access and reimbursement strategy designed to enable timely, equitable access

    Access and reimbursement strategy designed to enable timely, equitable access Advanced discussions with largest commercial payers >15 Medicaid agencies representing ~80% of individuals with SCD in the US are in discussions2 Active engagement with CMMI on innovative payment demonstration (anticipated

  12. Slide 12: Large patient population with projected demand for gene therapy

    Large patient population with projected demand for gene therapy 1. 70% figure supported by seven years of internal and external market research; 2. Potential addressable population of 20,000; 3. Data on file; 4. Komodo claims data >20K individuals with sickle cell disease in the U.S. may be addresse

  13. Slide 13: A potential multi billion-dollar opportunity with 20,000 addressable patients in the U.S.

    2 A potential multi billion-dollar opportunity with 20,000 addressable patients in the U.S. Strong commercial strategy and projected patient and physician demand Experienced commercial gene therapy team well-positioned to launch LYFGENIA™ 18-month commercial head start leveraging significant ZYNTEGL

  14. Slide 14: ZYNTEGLO and LYFGENIA manufacturing process

    ZYNTEGLO® manufacturing process Delivering a consistent manufacturing process is essential for patients, families and providers STAGE 2◇ 70-90 days Bulk of time spent on release testing to deliver high quality drug product Apheresis & Cell Collection Drug Product Manufacturing & Testing Drug Product

  15. Slide 15: Established gene therapy leader poised to unlock shareholder value

    Established gene therapy leader poised to unlock shareholder value Established Clinical Leadership 10+ years of gene therapy research 180+ patients treated 8 clinical trials Experienced team 100% focused on successfully commercializing gene therapy in the US Demonstrated Regulatory Success Establish

  16. Slide 16: Thank you to the SCD community

    to the SCD warriors, caregivers, advocates, healthcare providers, investigators, HCPs, and our bluebird team who made this milestone possible.

  17. Slide 17: Rich Colvin, MD, PhD chief medical officer Andrew Obenshain chief executive officer Tom Klima

    Rich Colvin, MD, PhD chief medical officer Andrew Obenshain chief executive officer Tom Klima chief commercial and operating officer

bluebird bio — Corporate Update (December 2023) on 6ix